Evopoint Biosciences USA Inc.
- Address
- 300 Baker Avenue Suite 300
Sponsor Overview
Specializations
Hospital-Acquired Bacterial Pneumonia
Clinical activity is centered on hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia and ventilated hospital-acquired bacterial pneumonia. The focus is on severe lower respiratory tract infections caused by Gram-negative bacteria in hospitalized adults.
- Ventilator-associated bacterial pneumonia
- Ventilated hospital-acquired bacterial pneumonia
- Gram-negative bacterial infections
This area reflects a therapeutic interest in serious inpatient respiratory infections that require intensive antimicrobial management.
Anti-Infective Therapy
The sponsor’s research landscape includes anti-infective therapy for resistant bacterial disease, with attention to treatment options for multidrug-resistant pathogens in the hospital setting. The work is aligned with clinical needs in severe bacterial pneumonia and complicated respiratory infections.
- Antibacterial treatment
- Resistant Gram-negative pathogens
- Severe respiratory infection
The therapeutic domain is focused on infection control in critically ill patients where effective antibacterial coverage is essential.
Critical Care Respiratory Medicine
Research involvement extends to critical care respiratory medicine, particularly infections arising in mechanically ventilated adults. The emphasis is on clinical conditions seen in intensive care environments, where respiratory infection can drive substantial morbidity and mortality.
- Mechanical ventilation
- Intensive care unit infections
- Severe pneumonia management
This clinical area intersects with the treatment of complex respiratory infections in hospitalized patients requiring advanced supportive care.
Hospital Infection Treatment
The sponsor is active in the treatment of hospital-acquired infections, with a specific focus on bacterial disease affecting the lungs. The therapeutic interest lies in infection management within acute-care settings, where pathogen resistance and patient fragility shape treatment priorities.
- Acute-care infection management
- Nosocomial bacterial disease
- Respiratory tract infection
The clinical emphasis is on infection-related outcomes in adults treated in hospitals and intensive care units.
Sponsored Trials
Data & Insights
This sponsor works with 4 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 17 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses1 trial180 other sponsors
Partnered Research Centres
17 centres- Address
- 27 Rue du Faubourg Saint-Jacques, 75014 Paris
- Address
- 46 Rue Henri Huchard, 75877 Paris
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- 1 Rond Point Du Pr Christian Cabrol, 80054 Amiens
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- 4 Place Du Professeur Robert Debre, Bp 40026, 30029 Nîmes
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Evopoint Biosciences USA Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.